Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cryoport Inc. (CYRX:NASDAQ), powered by AI.
Cryoport Inc. is currently trading at $14.71. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Cryoport Inc. on Alpha Lenz.
Cryoport Inc.'s P/E ratio is 9.4.
“Cryoport Inc. trades at a P/E of 9.4 (undervalued) with strong ROE of 17.3%.”
Ask for details →Cryoport Inc. is a global provider specializing in temperature-controlled logistics solutions for the life sciences industry. Its primary function is to ensure safe and efficient transportation of temperature-sensitive materials, including biological samples, pharmaceuticals, and other life sciences products. Notable for its comprehensive solutions, Cryoport offers a range of services including cryogenic transportation, monitoring, and logistics management, which are vital for maintaining product integrity and regulatory compliance. The company's offerings significantly impact sectors such as biotechnology, pharmaceuticals, and medical research, where precision and reliability are crucial. Cryoport's logistic services support the entire lifecycle of biopharmaceuticals, from research and development to clinical trials and commercialization. Cryoport's role in the financial market is underscored by its contribution to sustaining critical supply chains in the rapidly growing life sciences sector, making it a cornerstone for companies that rely on precise and secure logistics for their valuable materials. Headquartered in Nashville, Tennessee, Cryoport's innovation and commitment to quality make it a key player in enhancing the global capabilities of temperature-controlled logistic solutions for sensitive biological materials.
“Cryoport Inc. trades at a P/E of 9.4 (undervalued) with strong ROE of 17.3%.”
Ask for details →Cryoport Inc. (ticker: CYRX) is a company listed on NASDAQ in the Industrials sector (Integrated Freight & Logistics). It has approximately 1,090 employees. Market cap is $737M.
The current price is $14.71 with a P/E ratio of 9.41x and P/B of 1.47x.
ROE is 17.31% and operating margin is -20.89%. Annual revenue is $176M.